Physician profile
David Mann
NPI 1366425670
$35,550.56
in general payments reported to CMS, 2019-2025
59 companies · $3,090 in 2025
The $3,090 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $11K · 2021: $6,832 · 2022: $2,983 · 2023: $2,764 · 2024: $7,421 · 2025: $3,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,185 · Consulting Fee: $4,900 · Education: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,184.97 |
| Consulting Fee | $4,900.00 |
| Education | $1,190.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $16,714.39 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Amgen INC. | $2,254.23 | 2019-2025 | Imdelltra (Amg757) |
| Merck Sharp & Dohme LLC | $2,100.55 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $1,949.77 | 2021-2025 | Ojjaara, Blenrep |
| Pfizer INC. | $1,651.82 | 2019-2025 | |
| Epizyme, INC. | $1,371.62 | 2020-2021 | |
| Astellas Pharma US INC | $1,184.35 | 2021-2025 | Xtandi, Padcev, Xospata |
| Incyte Corporation | $1,035.04 | 2023-2025 | Monjuvi, Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $751.97 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $608.49 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Genentech USA, INC. | $572.89 | 2022-2025 | Tecentriq, Polivy, Columvi |
| Regeneron Healthcare Solutions, INC. | $469.67 | 2022-2025 | Libtayo |
| Celgene Corporation | $450.42 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Myriad Genetic Laboratories, INC. | $353.86 | 2021-2024 | Bracanalysis Cdx, Precisetumor |
| Janssen Biotech, INC. | $332.32 | 2019-2025 | Akeega, Balversa, Erleada |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.